Maxim Group analyst Anthony Vendetti reiterated a Buy rating on NeuroOne Medical Technologies yesterday and set a price target of $3.00.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Anthony Vendetti has given his Buy rating due to a combination of factors including NeuroOne Medical Technologies’ impressive preliminary revenue results for FY25, which exceeded both consensus and internal estimates. The growth is attributed to the strategic partnership with Zimmer Biomet, which has enhanced the company’s sales capabilities and contributed to increased procedure volumes.
Additionally, the company’s efforts in building awareness through partnerships with patient advocacy groups and media exposure have bolstered interest in its innovative treatments. NeuroOne’s advancement in its broader platform, including new applications for facial pain and spinal cord stimulation, further demonstrates its potential in addressing large market opportunities. The company’s strong financial position, with sufficient capital to operate into FY27, and its compelling valuation, support the reiterated Buy rating.
NMTC’s price has also changed dramatically for the past six months – from $0.433 to $1.060, which is a 144.80% increase.